{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A+PROTEIN+level&page=22",
    "query": {
      "intervention": "A PROTEIN level",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 1383,
    "total_pages": 139,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A+PROTEIN+level&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A+PROTEIN+level&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T20:13:04.445Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00921310",
      "title": "Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2009-09",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2016-12-13",
      "last_synced_at": "2026-10-15T20:13:04.445Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00921310"
    },
    {
      "nct_id": "NCT06225310",
      "title": "A Trial of Selinexor, Ruxolitinib and Methylprednisolone",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma in Relapse",
        "Multiple Myeloma, Refractory"
      ],
      "interventions": [
        {
          "name": "Selinexor",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oncotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 30,
      "start_date": "2024-08-06",
      "completion_date": "2027-05-01",
      "has_results": false,
      "last_update_posted_date": "2025-01-16",
      "last_synced_at": "2026-10-15T20:13:04.445Z",
      "location_count": 1,
      "location_summary": "West Hollywood, California",
      "locations": [
        {
          "city": "West Hollywood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06225310"
    },
    {
      "nct_id": "NCT04605913",
      "title": "Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreas Cancer",
        "Metastatic Pancreatic Cancer",
        "Pancreatic Adenocarcinoma",
        "Metastatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Modified GCN+TTF treatment",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2022-04-25",
      "completion_date": "2027-02-17",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-15T20:13:04.445Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04605913"
    },
    {
      "nct_id": "NCT01795170",
      "title": "Neurodevelopmental Outcome of Early Dietary Lysine Restriction in Pyridoxine Dependent Epilepsy Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pyridoxine Dependant Epilepsy"
      ],
      "interventions": [
        {
          "name": "Lysine Restricted Diet",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Pyridoxine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "University of British Columbia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "3 Years",
        "sex": "ALL",
        "summary": "3 Months to 3 Years"
      },
      "enrollment_count": 0,
      "start_date": "2013-04",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2014-09-30",
      "last_synced_at": "2026-10-15T20:13:04.445Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Seattle, Washington",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01795170"
    },
    {
      "nct_id": "NCT05131022",
      "title": "A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia (CLL)",
        "Small Lymphocytic Lymphoma (SLL)",
        "Diffuse Large B Cell Lymphoma (DLBCL)",
        "Follicular Lymphoma (FL)",
        "Mantle Cell Lymphoma (MCL)",
        "Marginal Zone Lymphoma (MZL)",
        "Waldenstrom Macroglobulinemia (WM)",
        "Primary Central Nervous System Lymphoma (PCNSL)",
        "Secondary Central Nervous System Lymphoma (SCNSL)"
      ],
      "interventions": [
        {
          "name": "NX-5948",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nurix Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 572,
      "start_date": "2022-04-13",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-10-15T20:13:04.445Z",
      "location_count": 18,
      "location_summary": "Duarte, California • San Francisco, California • Denver, Colorado + 15 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05131022"
    },
    {
      "nct_id": "NCT03576469",
      "title": "A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "CVI - Common Variable Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "C1-esterase inhibitor [recombinant] (C1-INH-R)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "IMMUNOe Research Centers",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2018-06-13",
      "completion_date": "2020-03-01",
      "has_results": false,
      "last_update_posted_date": "2021-02-15",
      "last_synced_at": "2026-10-15T20:13:04.445Z",
      "location_count": 1,
      "location_summary": "Centennial, Colorado",
      "locations": [
        {
          "city": "Centennial",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03576469"
    },
    {
      "nct_id": "NCT02818283",
      "title": "Soy Modulation of Immune Activation, LDL- Levels, and Lowering Inflammation by Pretzel Isoflavone Dietary Intervention",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Human Immunodeficiency Virus (HIV) Infection",
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Soy Pretzel",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Wheat Pretzel",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2016-06",
      "completion_date": "2023-10",
      "has_results": false,
      "last_update_posted_date": "2023-10-06",
      "last_synced_at": "2026-10-15T20:13:04.445Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02818283"
    },
    {
      "nct_id": "NCT02768766",
      "title": "Intermittent Selumetinib for Uveal Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Uveal Melanoma"
      ],
      "interventions": [
        {
          "name": "Selumetinib, 100mg",
          "type": "DRUG"
        },
        {
          "name": "Selumetinib, 125mg",
          "type": "DRUG"
        },
        {
          "name": "Selumetinib, 150mg",
          "type": "DRUG"
        },
        {
          "name": "Selumetinib, 175mg",
          "type": "DRUG"
        },
        {
          "name": "Selumetinib, 200mg",
          "type": "DRUG"
        },
        {
          "name": "Selumetinib, 225mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shaheer A. Khan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2017-02-28",
      "completion_date": "2020-09-18",
      "has_results": false,
      "last_update_posted_date": "2023-08-31",
      "last_synced_at": "2026-10-15T20:13:04.445Z",
      "location_count": 3,
      "location_summary": "New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02768766"
    },
    {
      "nct_id": "NCT04037254",
      "title": "Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Adenocarcinoma",
        "Stage IIC Prostate Cancer AJCC v8",
        "Stage III Prostate Cancer AJCC v8",
        "Stage IIIA Prostate Cancer AJCC v8",
        "Stage IIIB Prostate Cancer AJCC v8",
        "Stage IIIC Prostate Cancer AJCC v8",
        "Stage IVA Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Gonadotrophin Releasing Hormone",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "NRG Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 22,
      "start_date": "2019-10-08",
      "completion_date": "2025-12-23",
      "has_results": true,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-15T20:13:04.445Z",
      "location_count": 94,
      "location_summary": "Gilbert, Arizona • Tucson, Arizona • Duarte, California + 77 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04037254"
    },
    {
      "nct_id": "NCT05867329",
      "title": "Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Ulcerative Colitis Acute"
      ],
      "interventions": [
        {
          "name": "Cyclosporine Injection (IV)",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine Oral Product",
          "type": "DRUG"
        },
        {
          "name": "Upadacitinib Extended Release Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Intravenous Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone Oral Product",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Berinstein, Jeffrey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 700,
      "start_date": "2023-09-30",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-15T20:13:04.445Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05867329"
    }
  ]
}